Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BH3-interacting domain death agonist (BID) is a pro-apoptotic member of the BCL-2 protein family that serves as a critical molecular bridge between the extrinsic (death receptor-mediated) and intrinsic (mitochondrial) apoptotic pathways. In its inactive state, BID resides in the cytosol. Upon receiving apoptotic stimuli, such as death receptor activation, BID is cleaved by caspase-8 or other proteases to form its active, truncated counterpart, tBID. Active tBID translocates to the outer mitochondrial membrane, where it directly activates the pro-apoptotic effectors BAX and BAK, leading to mitochondrial outer membrane permeabilization (MOMP), the release of cytochrome c and SMAC/DIABLO, and subsequent caspase activation.
Dysregulation of BID is heavily implicated in various pathologies, including cancer, where its downregulation or inactivation contributes to apoptotic resistance and chemotherapy evasion. Conversely, hyperactivation of BID-mediated cell death is associated with neurodegenerative diseases, stroke, and ischemic injuries. Consequently, BID is a highly attractive therapeutic target. Small-molecule inhibitors of BID (such as BI-6C9 and BI-11A7) are being investigated to prevent pathological cell death in neurodegeneration and ischemia. On the other hand, BH3 mimetics (such as venetoclax and navitoclax) mimic the BH3 domain of BID and other BH3-only proteins to neutralize anti-apoptotic BCL-2 family members, thereby restoring the apoptotic cascade in cancer cells.
Direct small-molecule inhibitors (such as BI-6C9 and BI-11A7) bind to BID and prevent its cleavage into active truncated BID (tBID), thereby blocking mitochondrial outer membrane permeabilization (MOMP) and protecting cells from apoptosis. Conversely, BH3 mimetics (such as venetoclax, navitoclax, and obatoclax) mimic the BH3 domain of BID and other BH3-only proteins to competitively bind anti-apoptotic BCL-2 family proteins, displacing endogenous BID/tBID to promote apoptosis in cancer cells.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BH3-interacting domain death agonist (BID).